Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study
Liver Cancer · 01.06.2026 · 1-13
DOI: 10.1159/000552808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 01.06.2026. Verfasst von Masayuki Ueno und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Atezolizumab plus bevacizumab (Atezo+Bev) is the most widely used first-line treatment for unresectable hepatocellular carcinoma (HCC), while lenvatinib remains a standard alternative. Previous studies suggest limited efficacy of Atezo+Bev in patients with HCC exhibiting a CRAFITY score of 2 (CRP ≥1 mg/dL and AFP ≥100 ng/mL). We conducted an international collaborative study to compare the efficacy of Atezo+Bev and lenvatinib stratified by the baseline CRAFITY score.
Methods
We retrospectively analyzed 994 patients who initiated Atezo+Bev or lenvatinib as first-line therapy for unresectable HCC between September 2017 and March 2024 across 11 hospitals in Japan and 13 hospitals in Taiwan. Patients were categorized by baseline CRAFITY score, and progression-free survival (PFS) and overall survival (OS) were compared between treatment groups.
Results
The median age of the patients was 71 years, and 770 (77.5%) were male. The baseline CRAFITY score was 0 in 375 patients (37.7%), 1 in 402 patients (40.4%), and 2 in 217 patients (21.8%). In patients with a CRAFITY-0 score, median PFS (10.8 vs. 9.4 months; p = 0.548) and OS (21.1 vs. 29.3 months; p = 0.074) did not differ significantly between Atezo+Bev and lenvatinib. Similar findings were observed in CRAFITY-1 patients, with median PFS of 6.0 vs. 6.1 months (p = 0.943) and OS of 12.7 vs. 15.1 months (p = 0.168). In contrast, among CRAFITY-2 patients, lenvatinib was associated with significantly longer PFS (2.3 vs. 4.4 months; hazard ratio, 0.66; p = 0.017), while OS did not differ significantly between treatments (5.7 vs. 9.1 months; hazard ratio, 0.90; p = 0.586). A significant interaction was observed between CRAFITY score (0/1 vs. 2) and treatment regimen (Atezo+Bev vs. lenvatinib) for PFS (p = 0.002). Consistent findings were observed in adjusted analyses.
Conclusion
Lenvatinib was associated with significantly longer PFS than Atezo+Bev in patients with a baseline CRAFITY score of 2. The CRAFITY score may be useful for identifying patients in whom lenvatinib could be considered as a first-line option, and prospective validation is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Kurashiki, Japan.
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
- Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Internal Medicine, Kaohsiung Medical University Hospital, and Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.
Zitieren
APA
Ueno, M., Su, Y. Y., Takai, A., Huang, Y. H., Morimura, H., Nishijima, N., Lin, S. M., Chang, C. W., Iwamoto, S., Nagatomo, S., Lai, H. C., Mitani, T., Ikeda, A., Uenoyama, Y., Umeda, M., Chen, S. C., Chuang, C. H., Lai, S. W., Lee, T. Y., …, & Seno, H. (2026). Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study. Liver Cancer, 1-13. https://doi.org/10.1159/000552808
Vancouver
Ueno M, Su YY, Takai A, Huang YH, Morimura H, Nishijima N, et al. Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study. Liver Cancer. 2026:1-13. doi:10.1159/000552808
BibTeX
@article{Ueno2026,
author = {Ueno, Masayuki and Su, Yung-Yeh and Takai, Atsushi and Huang, Yi-Hsiang and Morimura, Hiroki and Nishijima, Norihiro and Lin, Shi-Ming and Chang, Ching-Wei and Iwamoto, Satoru and Nagatomo, Shu and Lai, Hsueh-Chou and Mitani, Takeshi and Ikeda, Atsuyuki and Uenoyama, Yoshito and Umeda, Makoto and Chen, San-Chi and Chuang, Chien-Huai and Lai, Shiue-Wei and Lee, Teng-Yu and Nakano, Shigeharu and Dai, Chia-Yen and Goto, Tomoyuki and Su, Tung-Hung and Hsu, Ching Sheng and Lo, Ching-Chu and Takeda, Haruhiko and Osaki, Yukio and Hatano, Etsuro and Lee, Pei-Chang and Lin, Po-Ting and Wang, Hung-Wei and Hsu, Wei-Fan and Liu, Tsung-Hao and Seno, Hiroshi},
title = {Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study},
journal = {Liver Cancer},
year = {2026},
pages = {1--13},
doi = {10.1159/000552808}
}
EUVIMED